Repeated oxygen drops during sleep do more than leave people exhausted. Animal research now points to a specific chemical chain running from the gut to the arteries, suggesting that the bacterial ecosystem in the intestines may be a hidden driver of heart damage in people with obstructive sleep apnea. Mouse studies show that the oxygen swings characteristic of the condition reshape gut bacteria and their chemical output within weeks, accelerating plaque buildup in arteries. The finding raises a pointed question: does the gut produce a reversible signal that worsens atherosclerosis only when cholesterol is already elevated?
How oxygen deprivation during sleep rewires gut chemistry
Obstructive sleep apnea, or OSA, causes the airway to collapse repeatedly during sleep, dropping blood oxygen and raising carbon dioxide in a pattern researchers call intermittent hypoxia and hypercapnia. The National Heart, Lung, and Blood Institute notes that untreated sleep apnea is linked to higher rates of stroke and heart attack, and summarizes these cardiovascular risks in its public information on sleep apnea. Standard treatment with continuous positive airway pressure, or CPAP, keeps the airway open and restores normal breathing. But CPAP does not appear to reverse every downstream consequence, and scientists have been searching for the biological pathways that connect disrupted breathing to damaged blood vessels.
A key piece of that puzzle emerged from mouse experiments that recreated the oxygen and carbon dioxide swings of OSA in a controlled setting. Researchers exposed mice to cycles of low oxygen and elevated carbon dioxide, then tracked changes in the animals’ intestinal bacteria and the small molecules those bacteria produce. The results, published in mSystems, showed that intermittent hypoxia and hypercapnia altered the gut microbiome and metabolome over time, establishing dysbiosis as a plausible bridge between apnea physiology and cardiometabolic disease. Bacterial communities shifted in composition, and the chemical environment of the gut changed alongside them.
One metabolite that drew particular attention is trimethylamine-N-oxide, or TMAO. Circulating TMAO originates from gut bacteria breaking down dietary compounds such as phosphatidylcholine, with the resulting trimethylamine absorbed in the small intestine and then oxidized in the liver. Separate animal work showed that intermittent hypoxia and hypercapnia accelerated atherosclerosis in genetically susceptible mice, and that the TMAO pathway was implicated as a partial mediator of that vascular damage. The word “partial” is significant: TMAO alone did not account for all of the increased plaque, pointing researchers toward additional gut-derived signals.
Bile acids, FXR, and the missing piece of the plaque puzzle
A follow-up line of investigation shifted the spotlight from TMAO to bile acids and a receptor called FXR, short for farnesoid X receptor. In atherosclerosis-prone ApoE-knockout mice fed a high-fat diet, exposure to intermittent hypoxia and hypercapnia produced measurable shifts in the gut microbiome alongside untargeted metabolomics changes that included altered bile-acid profiles, according to research published in Frontiers in Physiology. Atherosclerotic lesion burden increased in those animals, and the metabolomic data suggested bile-acid signaling was disrupted in tandem with the bacterial changes.
FXR sits at the intersection of bile-acid metabolism and vascular biology. Earlier pharmacologic studies in LDLR-knockout and ApoE-knockout mice demonstrated that activating FXR reduced atherosclerotic lesion formation, while blocking the receptor worsened plaques. That work established FXR not simply as a gut receptor but as a modulator of plaque biology. When these results are read alongside the OSA mouse data, a hypothesis takes shape: the oxygen swings of sleep apnea may selectively deplete bile acids that normally activate FXR, removing a brake on plaque growth. Because the ApoE-knockout and LDLR-knockout models both require elevated cholesterol to develop lesions, the effect appears to depend on an already disturbed lipid environment.
A 2023 review in Nature Reviews Cardiology mapped how different OSA subtypes and mechanistic pathways relate to cardiovascular risk, cataloging established routes such as sympathetic nervous system activation, systemic inflammation, and endothelial dysfunction. The gut–bile-acid–FXR axis represents a newer addition to that list, one that could operate in parallel with or amplify those better-known pathways. If bile-acid depletion proves to be a distinct and reversible signal, it could open a treatment angle that CPAP alone does not address.
What human data still need to show
The animal evidence is consistent and mechanistically detailed, but several gaps stand between these mouse findings and clinical action. No human cohort study has yet traced specific OSA-induced bile-acid or TMAO shifts to measured plaque progression or cardiovascular events in the same patients over time. The mouse papers report lesion area and 16S ribosomal RNA microbiome results, yet they lack direct FXR activity assays or tissue-specific readouts in vascular cells. That leaves open questions about where, and how strongly, this receptor is being modulated in the context of intermittent hypoxia.
Another limitation is that the most compelling data come from mice engineered to be highly susceptible to atherosclerosis and fed high-fat, high-cholesterol diets. Those models are useful for revealing mechanisms but may exaggerate effect sizes compared with typical human patients who have milder lipid abnormalities. It remains uncertain whether the same microbiome and bile-acid shifts occur in people with OSA whose cholesterol is controlled with statins or lifestyle changes, or in those with only modest plaque burden at baseline.
Human observational studies have begun to link OSA with cardiovascular outcomes, but they have not yet drilled down to the gut level in a systematic way. The National Heart, Lung, and Blood Institute has highlighted research that explains increased cardiovascular risks in people with obstructive sleep apnea, underscoring that patients with OSA show higher rates of hypertension, coronary disease, and heart failure in clinical cohorts, as summarized in an NHLBI research update. These studies, however, typically focus on hemodynamics, autonomic tone, and vascular stiffness, rather than microbiome composition or bile-acid signatures.
To bridge the gap, researchers would need longitudinal human studies that combine sleep monitoring, detailed lipid profiling, stool and blood metabolomics, and imaging of atherosclerotic plaques. Such work could clarify whether specific patterns of gut dysbiosis or bile-acid depletion track with worsening carotid intima–media thickness or coronary calcium scores in OSA patients. Interventional trials might then test whether targeting these pathways-through diet, prebiotics, probiotics, bile-acid derivatives, or FXR agonists-adds benefit on top of CPAP in reducing cardiovascular risk.
Designing those trials will not be straightforward. OSA is heterogeneous: some patients have predominantly hypoxic stress, while others experience more arousals and sympathetic surges. Comorbidities such as obesity, diabetes, and nonalcoholic fatty liver disease also influence both the microbiome and bile-acid metabolism, potentially confounding attempts to isolate an apnea-specific signal. Careful phenotyping and stratification will be essential to tease apart which patients are most likely to exhibit the bile-acid–FXR mechanism suggested by the mouse work.
From mechanism to potential therapies
If future human data confirm that OSA drives a reversible gut–bile-acid–FXR signal that worsens atherosclerosis in the setting of high cholesterol, several therapeutic avenues could emerge. One strategy would be to restore or mimic the bile acids that activate FXR, using either pharmacologic agonists or modified bile-acid formulations. Another would be to reshape the gut microbiome itself, encouraging bacterial communities that produce a more favorable bile-acid pool and fewer pro-atherogenic metabolites such as TMAO.
Any such approach would almost certainly be additive rather than a replacement for CPAP, which directly addresses the disordered breathing that initiates the problem. But for patients who remain at elevated cardiovascular risk even with well-controlled apnea, a gut-targeted therapy could represent a second front in the fight against plaque progression. The challenge now is to move from elegant mouse models to rigorous human studies that test whether this mechanistic insight can translate into measurable protection for the heart and arteries.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
